New Combination Drug for Older Adults with B-Cell Lymphoma
Part of Cancer clinical trials.
This study tests whether a new three-drug combination (Pola-ZR-Glo) works safely and effectively for older adults with a type of blood cancer called large B-cell lymphoma who cannot or prefer not to receive standard chemotherapy. The goal is to find a gentler treatment option for frail or elderly patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Confirmed diagnosis of large B-cell lymphoma (a type of blood cancer) without brain or spinal cord involvement
- Age 70 or older AND either medically frail, has other health problems that make standard chemo risky, or chooses not to have standard chemo
- Measurable tumors visible on scans (lymph nodes larger than 1.5 cm or other tumor sites larger than 1 cm)
- Never received anti-lymphoma drugs before (except steroids like prednisone)
- Adequate liver, kidney, and bone marrow function based on blood tests
- No uncontrolled blood clots, serious infections, or significant heart problems
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether an AI-guided treatment plan works better than a standard drug combination for older adults with a type of lymphoma. It is for people who are age 70 or older, have not had treatment before, and are considered less fit for strong chemotherapy.
This trial tests a new combination of drugs (Pola-ZR2) against a standard combination (ZR2) for older adults with newly diagnosed diffuse large B-cell lymphoma. It aims to see if the new mix is more effective and safe.
This trial tests if adding another drug (X) to a standard chemotherapy mix (Pola-RCHP) works better for people with untreated diffuse large B-cell lymphoma (DLBCL). It is for those whose cancer DNA levels did not drop enough after the first round of treatment.
This trial tests a combination of three drugs (Polatuzumab, Rituximab, and Orelabrutinib) for elderly patients who are frail or over 80 with a specific type of untreated diffuse large B-cell lymphoma (non-GCB DLBCL). The goal is to see if this drug combo is safe and effective for those who may not tolerate standard chemotherapy.
This trial tests a combination of three targeted drugs (polatuzumab vedotin, zanubrutinib, and R-CHP) for people newly diagnosed with a specific subtype of DLBCL called non-GCB. The goal is to see if this powerful mix can work better than standard treatment.
This trial tests a combination of four medications (pomalidomide, rituximab, orelabrutinib, and polatuzumab vedotin) for newly diagnosed, elderly patients with diffuse large B-cell lymphoma (DLBCL) who cannot tolerate standard treatments. It aims to see if this combination is effective and safe for older adults.
Hear when a new Large B-Cell Lymphoma (LBCL) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.